Astellas Pharma Europe has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for telavancin. Telavancin, a bactericidal, once-daily injectable lipoglycopeptide antibiotic, is meant for
Cyclacel Pharmaceuticals (Cyclacel) has reported topline survival data for the primary endpoint of the phase 2 study of sapacitabine. It is intended for the treatment of elderly patients
Banner Pharmacaps has signed an agreement with Midway Importing for the exclusive marketing and distribution of its Gelcaps Primero la Familia product line in the US. Banner’s Gelcaps
EKR Therapeutics has received notice of patent allowance from the US Patent and Trademark Office (USPTO) for its Ready-to-Use (RTU) Cardene I.V. (nicardipine hydrochloride) Premixed Injection. Once issued,
The Society of Chemical Manufacturers and Affiliates (SOCMA) has reported that the FDA has responded to its citizen’s petition after four years, calling on the agency to do
GlaxoSmithKline(GSK) reported an increase of 11% in third quarter earnings and is expecting to earn more from its swine flu vaccines in the final quarter of 2009. GSK
The product previously referred to on a pre-commercial basis as the Unilife Ready-to-Fill Syringe (or Unilife Prefilled Syringe) will henceforth be marketed and referred to as the Unifill
GTX Corp and MNX have entered into an exclusive product test agreement to develop a proprietary GPS enabled transport container. Over the following 2 quarters the companies will
ZymoGenetics has initiated phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection (EMERGE study). The first patient
Genmab has reached a milestone for Arzerra (ofatumumab) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately $23m was triggered by the FDA
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.